Pharmaceutical packaging systems are integral to maintaining drug products’ safety, efficacy, and stability throughout their lifecycle. These systems safeguard pharmaceutical products from environmental factors, contamination, and physical damage during storage, transportation, and use [1] . In addition to providing protection, they facilitate precise dosing, support efficient drug administration, and ensure compliance with regulatory standards. Advancements in technology have enabled the development of innovative packaging materials and designs, enhancing drug stability, promoting patient adherence, and reducing the environmental impact of pharmaceutical packaging [1] .

The complexity of packaging systems lies in their multifaceted roles, which include protecting and preserving drug products over extended periods [2] . Each component is selected based on its material properties and functional requirements and can be classified as primary, secondary, tertiary, or ancillary, as detailed in Table 1 [2] . Primary packaging, which directly contacts the drug product, is vital for maintaining stability and efficacy. Secondary packaging provides an additional layer of protection, while tertiary packaging is used for bulk transportation and storage. Though not formally categorized, ancillary items, such as desiccants and adhesive tapes, can still influence drug product quality and safety [2] [3] .

The Center for Drug Evaluation and Research (CDER), under the 21 Food, Drug, and Cosmetic Act (FD&C Act), mandates that drug product containers and closures must not interact with the drug in ways that compromise its safety, identity, strength, quality, or purity [4] . These materials must also shield the drug product from environmental factors that could lead to contamination or degradation. However, the chemical composition of packaging materials can sometimes interact with drug formulations, potentially affecting their stability, compatibility, and therapeutic effectiveness [4] .

One of the primary safety concerns related to packaging is contamination caused by extractable and leachables (E&L) [5] . These substances include organic and inorganic chemical entities that may migrate from packaging or manufacturing materials into the drug product [4] . Extractables are typically released under laboratory conditions that simulate extreme interactions, while leachables migrate under average storage or use conditions. For instance, leachables from secondary packaging materials, such as adhesives and inks, can accumulate in drug products, compromising their safety, efficacy, and stability [5] .

Qualifying a pharmaceutical packaging system involves demonstrating its protective, functional, and compatible properties while ensuring it does not pose safety risks [5] . Early-stage evaluation of container closure systems during drug development is strongly recommended. By the later stages, comprehensive studies should validate the packaging system’s safety and compatibility, supporting regulatory submissions [5] [6] .

Although no globally harmonized guideline for E&L assessments exists, organizations like the Product Quality Research Institute (PQRI) have published vital recommendations, particularly for high-risk dosage forms such as inhalation and parenteral products [6] . These recommendations, alongside guidance from the FDA, EMA, ICH, USP, and ISO, provide valuable frameworks for conducting E&L studies throughout the drug development lifecycle [7] .

No universally enforceable monographs specifically address assessing extractable and leachables (E&L) in pharmaceutical packaging and delivery systems [5] . However, regulatory authorities such as the FDA, USP, ICH, and Health Canada have established comprehensive guidelines to ensure that packaging systems comply with relevant compendial standards. For example, the FDA emphasizes detailed Chemistry, Manufacturing, and Controls (CMC) documentation in its guidance on container closure systems and associated devices, as summarized in Table 2 [8] .

In addition to FDA regulations, the USP monographs provide critical insights into the material properties of packaging systems, ensuring their safety and suitability. For instance, USP < 661 > outlines guidelines for assessing plastic materials, focusing on their composition, chemical properties, and suitability for pharmaceutical use [8] . Similarly, USP < 662 >, currently under development, will address the safety and suitability of metal materials in pharmaceutical packaging. Each enforceable monograph is typically paired with an informational counterpart to provide additional guidance. The key USP chapters for various materials of construction are listed in Table 3 [5] [8] .

Note: Chapters below 1000 are enforceable, while those above 1000 serve as informational guidelines.

The USP provides specific guidance for E&L assessments in chapters < 1663 > and < 1664 > [6] [7] . USP < 1663 > focuses on evaluating extractable, offering methodologies to identify potential chemical entities that could migrate from packaging materials. USP < 1664 > complements this by detailing procedures for assessing leachables under average storage and use conditions [9] . Although these chapters are not enforceable, they are vital for manufacturers aiming to develop robust E&L testing strategies that ensure product safety [6] [7] .

Extractables and leachables studies are generally conducted during the later stages of drug development. However, initiating the assessment of container closure systems at earlier stages can significantly enhance product safety and regulatory compliance [10] . Due to the inherent complexity of packaging systems, multiple testing steps are required to ensure compatibility between the drug product and its packaging [10] .

The evaluation process follows a three-tiered approach to packaging system qualification ( Table 4 ), comprising:

The design of an extractable and leachables (E&L) study is significantly influenced by the dosage form and its route of administration, as these factors determine

the extent of interaction between the drug product and its packaging materials [5] . Dosage forms vary widely in their potential for such interactions, necessitating a tailored approach to E&L risk assessment for each type [5] .

The FDA’s container closure guidance identifies inhalation dosage forms as the highest risk, requiring extensive evaluation due to their direct interaction with sensitive biological systems, such as the lungs [6] . Similarly, injectable solutions are classified as high risk because they come into direct contact with the bloodstream, and the solubility and reactivity of liquids can facilitate the migration of leachables [5] [6] .

Conversely, solid dosage forms, such as tablets and capsules, are considered low risk because they lack solvents and moisture that typically enhance the extraction of packaging components. These forms exhibit minimal interaction with their packaging materials [8] . Semi-solid and liquid forms—such as solutions, ointments, and creams—pose moderate risk levels due to solvents, increasing the likelihood of extracting chemical entities from packaging materials [8] .

Even low-risk dosage forms, such as oral or topical products, require a documented material risk assessment to evaluate the suitability of container closure systems. This risk-based prioritization helps allocate resources effectively for E&L testing, ensuring patient safety without overburdening the evaluation process (refer to Table 5 ) [8] .

This risk-based approach ensures that E&L testing is targeted appropriately, focusing on the likelihood and severity of package-drug interactions [8] .

The selection of packaging materials is an integral part of drug development, closely tied to the dosage form and its route of administration. A systematic evaluation ensures that the packaging system aligns with the specific needs of the drug product, considering its complexity and functionality [12] .

1) Material Suitability and Initial Assessments

In the initial stages, the focus is on assessing the suitability of packaging materials using vendor-supplied data and literature sources. At this point, extractables studies are not conducted. Instead, the evaluation centers on understanding the material’s composition and identifying critical components most likely to interact with the drug product [12] .

2) Key Steps in Material Assessment

Although ICH Q3B(R) guidelines address drug-related impurities, they do not cover extractables and leachables (E&L) arising from non-drug components like packaging and delivery systems [7] . Industry groups like the PQRI leachables and

Extractables Working Group have established thresholds for E&L risk evaluation to address this gap. These thresholds provide a framework for identifying, assessing, and mitigating the risks associated with leachables, ensuring regulatory compliance and patient safety. The definitions and PQRI recommendations for these thresholds are detailed in Table 7 [11] .

E&L studies should follow a staged approach to evaluate packaging systems systematically. This ensures data aligns with regulatory expectations and supports product safety across the drug lifecycle [5] [8] .

By adhering to this systematic approach, as described in Table 8 , manufacturers can generate robust data sets, support regulatory submissions, and ensure patient safety.

A controlled extraction study is a laboratory investigation designed to qualitatively and quantitatively analyze the extractable profile of critical components in a container closure system. It marks the first step in the chemical characterization of packaging material and provides crucial insights for selecting appropriate materials [18] . It helps meet regulatory expectations and ensures the safety of materials to control leachables in the final dosage form. The experimental protocol for a controlled extraction study should be meticulously crafted to establish a meaningful correlation between packaging materials and drug product interactions. Several factors must be considered in designing a controlled extraction study [11] [14] .

The most practical way to begin a controlled extraction (CE) study is by identifying and selecting the critical components of the container closure system, such as vials, stoppers, seals, and syringes, especially those in direct contact with the drug product [15] . Evaluating the chemical composition of these packaging components can provide potential clues for toxic elements such as nitrosamines and PANs, which can often arise from materials like carbon black or sulfur curing agents [10] . It is recommended that vendor chemical composition information be obtained during the material screening process before initiating extraction studies. The effect of manufacturing processes, such as heat sterilization, must be carefully examined during the study design [16] [18] .

When selecting components for a controlled extraction study, it is crucial to prioritize primary packaging materials, given their direct contact with the drug product. The extent of extractables is influenced by the material type, including plastics, elastomers, glass, metals, and coatings [19] . While primary packaging is prioritized due to its potential for extractable, secondary packaging (e.g., labels, adhesives) and functional systems (e.g., inhalers, pre-filled syringes) are also assessed for compatibility. The study’s focus also varies with the type of dosage form: for parenteral products, the emphasis is on rubber stoppers, vials, and IV bags; for ophthalmic products, on dropper bottles and their caps; and for inhalation products, on inhaler devices and associated components [6] [10] . This comprehensive approach ensures patient safety, material suitability, and compliance with regulatory requirements [20] .

Once the components and their chemical profiles have been evaluated, the next critical step is selecting appropriate extraction solvents to ensure comprehensive analysis [21] . The extraction solvents should be based on USP < 1663 >, and the selection of proper solvents must encompass a wider polarity range that can extract various chemical compounds that could become potentially leachable ( Table 9 ). The solvent range should consider the drug product composition and be able to bracket the pH range of the formulation that could extract organic extractable. The study should also include additional solvents for extractable elements [18] .

To maximize extraction efficiency, the components can be introduced into the selected solvents by pressing, grinding, or cutting them into small pieces to increase the contact surface area of the component in the solvent [19] . Controlled extraction studies must be performed on individual components, although elements of the same material can be combined. The major drawback of combining components is the inability to track the source of impurity during leachable study [19] [20] .

Multiple extraction techniques like reflux, Soxhlet, microwave digestion, etc., should be employed to extract a wide range of compounds, including volatile organic compounds [19] . The extraction ratio between solvent and material is guided by the Analytical Evaluation Threshold (AET). The ratio must be high enough to achieve the AET level with the applicable analytical methods. Further, the selection of extraction time, extraction temperature, and extraction methods that will mimic or amplify the clinical conditions of contact between drug product/packaging system configurations should aim to derive maximum extracts without compromising the packaging components’ integrity or degrading the extractable compounds that it does not provide adequate, useful information [21] .

Once an extract is generated, the extracted sample solutions are prepared for analytical testing, with adjustments such as dilution or concentration based on AET requirements [21] . The next step is its chemical characterization, which involves qualitative and quantitative assessments across four key stages: scouting, discovery, identification, and quantitation. Scouting provides a preliminary screening to detect potential extractables, followed by discovery to uncover unexpected or unknown compounds. Identified compounds are matched with reference standards or spectral libraries, and advanced techniques like MS/MS or NMR are used when needed [21] .

Appropriate analytical methods are selected to detect various volatile, semi-volatile, and non-volatile organic and inorganic compounds. However, it is impossible to validate these methods in advance, as the structures of the extractables are unknown [20] . Instead, methods are chosen for their ability to provide broad coverage and sensitivity, ensuring comprehensive detection and characterization of extractables. Various analytical techniques are employed to detect different types of extractables, as outlined in Tabe 10 [18] .

Depending on the container closure system (CCS) material, additional analytical methods may be required to target specific extractables of concern [14] . For example, when analyzing extractables from elastomers, methods capable of detecting low levels of mutagenic compounds, such as nitrosamines and 2-mercaptobenzothiazole, may be necessary. Similarly, if the CCS contains carbon black, analytical methods sensitive to low levels of polycyclic aromatic hydrocarbons (PAHs) must be employed [16] .

Standard reference materials are selected to represent common extractable compounds found in polymeric materials. For LC-UV/MS analysis, at least one standard must be detected in each mode (positive ionization, negative ionization, or UV) [13] . MS standards may show different response levels, so their concentrations should be adjusted to ensure accurate quantitation.

It is optional to identify all peaks observed during extractable analysis. Only peaks observed above AET should be identified using a clearly defined identification. Also, only peaks not observed in the extraction blank are labeled as extractables [18] . Hence a blank solvent extract must be prepared in the same manner as the sample and analyzed before sample analysis. Suppose a peak in the blank is also observed at a significantly higher response level in the sample extract. In that case, the peak should also be labeled as extractable, and the background corrected for the area in the blank during the semi-quantitation step [18] .

The controlled extraction study provides critical data on potential extractables that may migrate into the drug product. Identifying and quantifying these extractables against safety thresholds allows toxicologists to assess risks and determine which compounds to monitor during stability studies, forming the basis for the leachable study [18] .

Another way to support the extractable-to-leachable risk assessment is through a simulated leachable study. A simulation study is a Controlled Extraction Study designed to produce an extractables profile that mimics the worst-case leachables profile of a drug product [19] . This approach offers a powerful predictive tool that allows researchers to anticipate potential leachables in drug products without waiting for the full shelf-life, which is particularly valuable for products with extended shelf life [19] [20] .

The extract generated in a simulation study should:

A simulation study involves placing the drug product or a placebo in contact with the packaging material under conditions that simulate actual storage [22] . Common temperature conditions for simulation studies include:

For products that require refrigerated or frozen storage, additional temperature conditions may include:

Alternatively, an extraction solvent can be selected to closely match the pH and solvating properties of the drug product. A placebo can be used for simple formulations, provided it does not interfere with the analytical methods employed for detecting leachables [21] . If neither the drug product nor the placebo is used, the extraction solvent must be carefully selected to ensure compatibility with the analytical techniques [22] .

The simulation study should be conducted on packaging materials that closely resemble their final intended use. This ensures that the resulting data accurately reflects the potential migration of compounds into the drug product, aiding in a more focused toxicological assessment [14] . While simulation studies offer a faster and more targeted approach than traditional leachables studies, there is a risk that certain extractable identified in more aggressive controlled extraction studies might not appear under the milder conditions used in simulation studies. Thus, careful interpretation of the results is essential to ensure a comprehensive risk assessment [19] [20] .

Leachable studies assess chemical entities that migrate from manufacturing and packaging components into pharmaceutical products under average storage and use conditions and during accelerated stability tests [21] . These studies also evaluate substances that may leach directly from medical devices during clinical use, potentially leading to patient exposure. Unlike extractables, which represent potential leachables and hypothetical risks, leachables migrate into the drug product, posing real safety concerns [21] .

A scientifically sound leachables assessment must involve validated, quantitative analytical methods based on those used in Controlled Extraction Studies (CES) [15] . The following points are essential in leachable studies:

Storage conditions for leachable studies should cover normal conditions, reflecting typical usage, and include accelerated conditions to simulate aging, along with worst-case scenarios [23] . For instance, worst-case scenarios can include storing containers in inverted or sideways positions to maximize the contact between the drug product and the container closure system (CCS) [22] . While higher temperatures are typically expected to increase leachables, in some cases, elevated temperatures can reduce leachable concentrations by altering the partitioning between the CCS and the product. Sampling should occur at regular intervals such as 1, 3, 6, 9, and 12 months, with extended intervals if necessary [22] .

The appropriate storage conditions, following ICH Q1A(R2), are shown in the Table 11 below:

Control samples stored in inert, non-reactive containers, such as glass bottles, are essential for accurate leachables studies. These control samples must be stored under the same conditions and durations as the stability samples, serving as a baseline to detect potential leachables [23] . Labels, adhesives, and inks should be avoided on control containers to prevent contamination. Comparisons between stability and control samples allow for the identification of leachable species. Including placebo samples stored in the CCS as part of the leachable study is strongly recommended. These samples can help confirm whether leachables are observed in the active [24] .

The analytical techniques used for CES serve as the foundation for developing and validating methods for leachables studies. Given that leachables may be present at very low levels and that drug matrices can interfere with detection, validated methods must meet stringent criteria, including accuracy, precision (repeatability and intermediate precision), specificity, limit of detection (LOD), limit of quantitation (LOQ), linearity, range, and robustness [24] . System suitability tests should be integrated into each method to ensure performance during analysis. Once the CES results are finalized, appropriate standards must be procured to validate the analytical methods used in the leachables study [24] [25] .

No further analytical steps are required if the leachable is identified in the extraction study and validated using the authentic material. However, if the authentic material is not used for method validation, it should be employed in additional validation experiments to confirm the method’s suitability for the leachable [25] . These extra tests may involve calculating a response factor, which could alter the results. In such cases, only the results calculated with the response factor should be reported [24] [25] .

Reporting leachables requires defining specific thresholds to determine the significance of the detected compounds. Based on total daily intake (TDI), these thresholds guide reporting and identification processes to ensure patient safety [11] . The following Table 12 outlines the reporting and identification thresholds used for leachables:

A minimum of three batches of drug product must be considered for leachable study. If the product has multiple strengths or packaging configurations, each should be represented in the study. These batches should be studied throughout the proposed shelf life of the product [26] [27] .

1) Sensitivity Limitations: Modern extractable and leachables (E&L) assessments face challenges in detecting compounds at trace levels, often in parts per billion (ppb) or lower, to ensure patient safety. Techniques like Liquid Chromatography-Mass Spectrometry (LC-MS) and Gas Chromatography-Mass Spectrometry (GC-MS) are highly sensitive but can encounter difficulties with compounds that have poor ionization efficiency or require specific derivatization for accurate detection [28] . Differentiating genuine leachables from background noise further complicates the process and can lead to false positives or negatives. Addressing these challenges involves employing advanced instrumentation such as high-resolution mass spectrometry (HRMS) to enhance sensitivity and mass accuracy, utilizing multiple ionization modes like Electrospray Ionization (ESI) and Atmospheric Pressure Chemical Ionization (APCI) to broaden the detection range for diverse compound classes, and developing robust signal-to-noise optimization protocols to ensure reliable quantification [12] [29] .

2) Matrix Effects: Complex matrices, such as drug formulations or biological fluids, pose significant challenges in extractable and leachables (E&L) assessments by interfering with analytical methods and causing ion suppression or enhancement, particularly in techniques like Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). These matrix effects can compromise quantitation and reproducibility, especially when analytes are at low concentrations. Addressing these issues requires thorough matrix evaluations during method development to identify and mitigate potential interference, using isotopically labeled internal standards to compensate for matrix effects, and implementing sample preparation techniques like solid-phase extraction (SPE) to eliminate interfering substances before analysis. Similarly, selectivity challenges arise when differentiating target leachables from structurally similar compounds, mainly when using spectroscopic methods such as Fourier Transform Infrared Spectroscopy (FTIR) or Ultraviolet-Visible Spectroscopy (UV-Vis), where overlapping peaks or lack of unique features can hinder accurate identification [29] These challenges can be addressed by pairing complementary techniques like Gas Chromatography-Mass Spectrometry (GC-MS) with Nuclear Magnetic Resonance (NMR) for confirmatory identification, applying chemometric tools and advanced spectral deconvolution algorithms to improve resolution, and employing targeted methods such as selected reaction monitoring (SRM) in LC-MS/MS to enhance selectivity [30] [31] .

3) Quantitative Limitations:

Accurate quantification of compounds across a broad dynamic range presents a significant challenge in extractable and leachables (E&L) assessments. High concentrations of extractable in packaging materials can saturate detectors, while ultra-sensitive quantification is required for trace levels of leachables in drug formulations. Addressing these issues involves calibrating instruments with a wide range of standards to ensure linearity across the dynamic range, employing multiple detectors, such as UV for high and MS for low concentrations, within the same workflow, and regularly validating and verifying calibration curves to maintain precision and accuracy. Similarly, managing and interpreting large datasets generated by advanced analytical methods pose data integrity and processing challenges [10] . Variability in analyst expertise and differences in data processing protocols can further complicate results. These challenges can be mitigated by implementing robust software tools for automated data analysis to reduce human error, rigorously training analysts in data interpretation to ensure consistency across studies and using statistical tools to evaluate reproducibility and precision across replicates [24] .

4) Method Validation: Addressing Challenges

Method validation ensures analytical techniques’ accuracy, precision, sensitivity, and reproducibility in extractable and leachables (E&L) studies. To address challenges, it is essential to rigorously evaluate validation parameters such as specificity, linearity, limit of detection (LOD), quantification (LOQ), accuracy, and robustness. For instance, specificity testing with spiked and unspiked matrices is critical to address matrix effects effectively. Interlaboratory validation studies further enhance method transferability and reproducibility, ensuring consistent results, which are crucial for regulatory submissions. Adopting a risk-based approach prioritizes validation efforts by focusing on highly toxic compounds or critical materials that pose significant safety concerns and optimizing resources while addressing the most pressing risks [18] . Continuous monitoring and periodic revalidation are necessary to maintain method relevance and accuracy as materials or formulations evolve, particularly in long-term stability studies or post-market surveillance [21] . By understanding and mitigating limitations such as sensitivity constraints, matrix effects, and data processing issues, researchers can achieve robust and reliable E&L assessments. Employing advanced technologies, risk-based strategies, and ongoing monitoring further ensures reliability and compliance, supporting safer and more efficient pharmaceutical development [24] .

Establishing a correlation between extractables and leachables is essential for interpreting, assessing, quantifying, and controlling the interactions between the drug product and the container closure system (CCS) [32] . A robust qualitative and quantitative correlation between the extractable and leachables profiles helps ensure product safety and compliance with regulatory requirements. The correlation process should account for results from extraction studies conducted on multiple batches of packaging or manufacturing components and leachable studies performed in various batches of the drug product across different stability storage time points [33] [34] .

A qualitative correlation is established by demonstrating that compounds detected in the leachable study are also present in the controlled extraction study. A quantitative correlation is confirmed by showing that the levels of leachables identified in the leachable study are consistently lower than or comparable to the levels of extractables found in the quantitative controlled extraction study [23] . This correlation confirms that the extraction study accurately predicts the leachables that may migrate into the drug product under real-world conditions [35] .

Toxicological risk assessment is the primary goal of extractable and leachables (E&L) studies. The involvement of toxicologists is crucial from the material selection stage, where they use vendor data to identify the presence of alert chemicals [15] [35] . Data from extractable studies help determine which compounds have the potential to become leachables, followed by evaluating their toxicity using available literature. Once a potential leachable is identified, further analytical testing confirms its presence and measures its concentration in the final drug product. The next step is calculating the leachables estimated daily intake (EDI), considering its concentration, the product’s dosage form, and the maximum daily dose based on the route of administration [36] . Toxicologists then collect relevant toxicological data from scientific literature, databases, and regulatory resources to assess the potential risks. In cases where direct toxicological data is lacking, predictive methods such as read-across approaches or structural alerts are used based on chemical similarities, and allometric scaling may be employed to extrapolate toxicological effects from animal studies to humans [37] . A margin of safety (MOS) is then calculated by comparing the estimated exposure and the no-observed-adverse-effect level (NOAEL) or other toxicity thresholds. If the MOS is sufficient, the leachable is deemed safe; if not, mitigation strategies, such as changes in packaging or formulation, may be recommended. This comprehensive process ensures an accurate toxicological evaluation, minimizing risks to patient safety and meeting regulatory compliance [38] .

The interpretation and application of toxicological data are essential for conducting robust risk assessments in extractable and leachables (E&L) studies. This process begins with identifying compounds extracted from materials or leached into products during storage or use. Toxicological evaluation determines which compounds require further assessment based on their concentration, structure, and potential toxicity. For example, if benzophenone is identified as a leachable in a polymeric container through GC-MS analysis, its concentration and toxicological profile are evaluated to assess potential risk. Safety thresholds such as the Permitted Daily Exposure (PDE) or the Threshold of Toxicological Concern (TTC) guide these evaluations. PDE values are derived using toxicological data like the No-Observed-Adverse-Effect Level (NOAEL), adjusted by safety factors to account for variability. In contrast, TTC values offer a conservative benchmark for compounds with limited toxicological data [27] [28] .

Exposure assessments involve quantifying a compound’s Estimated Daily Intake (EDI) based on product use and comparing it against these safety thresholds. For instance, if the concentration of benzophenone in a medication is 0.05 mg/L and a patient consumes 2 L/day, the EDI would be 0.1 mg/day, then compared to the PDE. Risk characterization assesses whether the EDI exceeds the threshold. If it does, mitigation strategies such as material substitution or process optimization are implemented. TTC is particularly useful for compounds with unknown toxicological data, providing a default threshold to guide decisions without requiring extensive testing. For example, a non-genotoxic packaging extractable with an exposure below 1.5 µg/day may not need further toxicological evaluation. PDE-based assessments, such as those for Bisphenol A (BPA) with a PDE of 4 µg/kg/day, compare patient exposure to the defined threshold to evaluate safety [29] .

Exceptional cases, like genotoxic impurities, apply much stricter thresholds, such as the 10 ng/day concern level per ICH M7 guidelines, ensuring patient safety. Challenges in toxicological interpretation include data gaps, cumulative or synergistic effects of multiple leachables, and considerations for vulnerable patient populations like pediatrics, where additional safety factors are applied. Strategies to address these include using in silico predictions, conducting cumulative exposure assessments, and employing stricter thresholds for specific populations. Integrating toxicological data into validated workflows enhances reliability, with robust analytical methods confirming compound identity and exposure models ensuring real-world applicability [39] . Practical examples, such as evaluations of benzophenone or BPA, illustrate how safety thresholds guide decision-making. Addressing data gaps and cumulative toxicity further strengthens assessments, ensuring patient safety and compliance with regulatory expectations [40] .

Ensuring the safety and efficacy of pharmaceutical products involves comprehensive Extractable and Leachable (E&L) studies. However, despite precise FDA requirements, many submissions fail to meet regulatory expectations due to gaps in study design, execution, and data interpretation. Addressing these deficiencies is critical to ensuring compliance, product quality, and patient safety.

In the evolving pharmaceutical and medical device industries, extractable and leachables (E&L) assessments are critical for product safety and regulatory compliance. A significant advancement in this field is integrating in silico predictive tools, which leverage computational models to estimate the likelihood of compound migration, toxicity, and interactions based on material composition and exposure conditions [30] [31] . These tools enable early-stage risk assessments, reducing reliance on extensive laboratory testing and providing a proactive approach to identifying and mitigating potential risks.

Maintaining pharmaceutical products’ highest quality and safety standards is critical to protecting patient health. Impurities from packaging materials, though not direct degradants, can migrate into drug products and pose risks over time. Conducting well-designed Extractable and Leachable (E&L) studies minimizes these risks and ensures product purity.

While general guidelines like USP < 1663 > and < 1664 > provide a framework, E&L studies must be tailored to the specific drug product, packaging system, and storage conditions. Early assessment during development allows manufacturers to address potential challenges, select appropriate analytical methods, and evaluate vendor-provided data, reducing the risk of delays. Incorporating thresholds such as the Analytical Evaluation Threshold (AET) and Safety Concern Threshold (SCT) ensures scientifically sound evaluations.

Thorough E&L studies support regulatory compliance and patient safety and deliver cost efficiencies by identifying risks early, avoiding market delays, and ensuring competitive advantage. A proactive approach strengthens product development and ensures the timely delivery of high-quality pharmaceuticals to patients.